Paper Details

  1. Home
  2. Paper Details

Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study).

Author: AbbateAntonio, AbouzakiNayef Antar, ArenaRoss, Biondi-ZoccaiGiuseppe, CanadaJustin McNair, DinarelloCharles Anthony, FalcaoRaquel Appa, JahangiriArehzo, KontosMichael Christopher, OddiClaudia, ShahKeyur Bharat, Van TassellBenjamin Wallace, VoelkelNorbert Felix

Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This double-blind, randomized, placebo-controlled crossover trial explores the effects of IL-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF) and elevated C-reactive protein (CRP) levels. The study finds that anakinra significantly reduces systemic inflammation and improves aerobic exercise capacity.
Paper Details　
Original Abstract of the Article :
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome of exercise intolerance due to impaired myocardial relaxation and/or increased stiffness. Patients with HFpEF often show signs of chronic systemic inflammation, and experimental studies have shown that interleukin-1 (IL-1)...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/24262762

データ提供：米国国立医学図書館（NLM）

Fighting Inflammation in Heart Failure

The field of [cardiology] is constantly striving to improve the lives of [patients with heart failure]. This study investigates the [impact of interleukin-1 (IL-1) blockade] on [aerobic exercise capacity] in [patients with heart failure with preserved ejection fraction (HFpEF)]. The authors found that [anakinra, an IL-1 blocker], significantly [improved exercise capacity] and reduced [plasma C-reactive protein (CRP) levels] in these patients, highlighting the potential of [IL-1 blockade] as a novel therapeutic approach for [HFpEF].

Anakinra: A Potential Treatment for HFpEF

The study found that [IL-1 blockade with anakinra] significantly [improved aerobic exercise capacity] and reduced [inflammation] in [patients with HFpEF]. This finding suggests that [targeting inflammation] may be a key to improving [outcomes] in this challenging condition.

Managing Heart Failure with Preserved Ejection Fraction

This research offers hope for [patients with HFpEF], a complex condition that can significantly impact [quality of life]. It suggests that [IL-1 blockade] may be a [promising therapeutic strategy] for [improving exercise tolerance] and potentially [slowing disease progression].

Dr.Camel's Conclusion

Heart failure, like a desert mirage, can be a deceptive and challenging condition. This study offers a glimmer of hope, suggesting that [targeting inflammation] may be a key to improving the lives of patients with [HFpEF].

Date :
  1. Date Completed 2014-02-25
  2. Date Revised 2023-11-11
Further Info :

Pubmed ID

24262762

DOI: Digital Object Identifier

NIHMS530697

Related Literature

Article Analysis
・Effects of anakinra
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.